Steinberg M I, Keller C E, Bemis K G
Clin Exp Hypertens A. 1985;7(10):1481-97. doi: 10.3109/10641968509073605.
We used microsphere techniques to determine cardiac output and tissue blood flows in chloralose-anesthetized spontaneously hypertensive rats treated with LY127210 (10 mg/kg, i.p.), hydralazine (2 mg/kg, i.p.), or saline. LY127210 decreased blood pressure, systemic vascular resistance, heart rate and left ventricular end-diastolic pressure. Regional vascular resistance fell in kidney, cerebral cortex, ileum and skin, and blood flow decreased in skin, and cerebral cortex. After hydralazine, blood pressure, systemic resistance and left ventricular end-diastolic pressure also decreased, but heart rate increased. Regional vascular resistance decreased in the kidney, cerebral cortex, ileum, myocardium and skeletal muscle, and blood flow was either maintained or increased in these tissues. Unlike LY127210, hydralazine decreased blood flow and increased vascular resistance in the skin. Thus, LY127210 reduces blood pressure in hypertensive rats by reducing vascular resistance, although about 1/3 of the fall in pressure was attributed to a decrease in cardiac output. Since heart rate, stroke volume and skin resistance did not increase, LY127210 might also interfere with baroreflex mechanisms.
我们运用微球技术测定了用LY127210（10毫克/千克，腹腔注射）、肼屈嗪（2毫克/千克，腹腔注射）或生理盐水处理的氯醛糖麻醉自发性高血压大鼠的心输出量和组织血流量。LY127210降低了血压、全身血管阻力、心率和左心室舒张末期压力。肾脏、大脑皮层、回肠和皮肤的局部血管阻力下降，皮肤和大脑皮层的血流量减少。使用肼屈嗪后，血压、全身阻力和左心室舒张末期压力也降低，但心率增加。肾脏、大脑皮层、回肠、心肌和骨骼肌的局部血管阻力降低，这些组织的血流量维持不变或增加。与LY127210不同，肼屈嗪使皮肤血流量减少，血管阻力增加。因此，LY127210通过降低血管阻力来降低高血压大鼠的血压，尽管约1/3的血压下降归因于心输出量的减少。由于心率、每搏输出量和皮肤阻力没有增加，LY127210也可能干扰压力反射机制。
